The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 25, 2019

Filed:

May. 16, 2014
Applicant:

Tyg Oncology Ltd., Nottinghamshire, GB;

Inventors:

Geert Cornelius Mudde, Breitenfurt, AT;

Paul Christopher Broome, Luton, GB;

Frederick William Jacobs, Derbyshire, GB;

Christof Langer, Vienna, AT;

Assignee:

TYG ONCOLOGY LTD., Nottinghamshire, GB;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 39/0005 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61K 47/549 (2017.08); A61K 47/6849 (2017.08); C07K 16/283 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/627 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01);
Abstract

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases.


Find Patent Forward Citations

Loading…